Glucocorticoid antiasthmatic prodrug; de-esterified in the lung to active metabolite. Anti-inflammatory.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 540.7. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.85 mL||9.25 mL||18.49 mL|
|5 mM||0.37 mL||1.85 mL||3.7 mL|
|10 mM||0.18 mL||0.92 mL||1.85 mL|
|50 mM||0.04 mL||0.18 mL||0.37 mL|
References are publications that support the products' biological activity.
Stoeck et al (2004) In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide. J.Pharmacol.Exp.Ther. 309 249 PMID: 14718604
If you know of a relevant reference for Ciclesonide, please let us know.
View Related Products by Target
Keywords: Ciclesonide, supplier, Glucocorticoid, antiasthmatic, prodrug, anti-inflammatory, Glucocorticoid, Receptor, Glucocorticoid, Receptor, Tocris Bioscience
Citations for Ciclesonide
Citations are publications that use Tocris products.
Currently there are no citations for Ciclesonide. Do you know of a great paper that uses Ciclesonide from Tocris? If so please let us know.
Reviews for Ciclesonide
There are currently no reviews for this product. Be the first to review Ciclesonide and earn rewards!
Have you used Ciclesonide?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.